The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...

Interim Analysis Expected End of 2Q 2025BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company ...

The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9% ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Nanomerics Ltd. announced the successful completion of its OC134 Phase I trial - the SUNLIGHT trial. With the clinical phase competed the trial for OC134 and the MET platform has met its primary ...

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services ...

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

A vaccine against norovirus, the dreaded “winter vomiting bug”, could be closer than you think: early clinical trials have ...

Title: Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne ...